Lundbeck Q3 2019 Financial Results
Lu AF11167: Addresses negative symptoms of schizophrenia that trouble
patients most
*
33
Negative symptoms most
bothersome symptom for patients
with schizophrenia
Primary cause for inability to live
independently, hold jobs, establish
personal relationships, and manage
everyday social situations
Widely recognized as important
features of schizophrenia
associated with changes in
emotions and behaviours
Difficult to treat; currently
available antipsychotics are not
considered effective
Prevalence
(major countries)
4.7m - Prevalence of
schizophrenia (G7)
*
*
Phosphodiesterase 10A inhibitor
(PDE 10Ai)
Potential novel MoA for the treatment
of negative symptoms in patients with
schizophrenia
Potentially maintaining control of
positive symptoms
*
3.5m - Treatment
prevalence (75%)
*
Phase II started in December 2018*
1.7m clinical stable
outpatients (50%)
*
Monotherapy
*
Two fixed-flexible doses +
0.8m - Negative
symptoms (40%)
placebo (BID)
~250 patients
Primary endpoint: Change from
baseline to Week 12 in BNSS
total score
Source: Decision Resource; Schizophrenia | Landscape &
Forecast 2018
*) NCT03793712.
BNSS: Brief Negative Symptoms Scale
LundbeckView entire presentation